Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease

Zheng Sheng Lai, Teng Kuang Yeh, Yu Chi Chou, Tsu Hsu, Cheng Tai Lu, Fang Chun Kung, Ming Yen Hsieh, Chun Hung Lin, Chiung Tong Chen, Che-Kun Shen, Weir Torn Jiaang

研究成果: 雜誌貢獻文章同行評審

3 引文 斯高帕斯(Scopus)

摘要

Reactivation of fetal hemoglobin (HbF) expression by therapeutic agents has been suggested as an alternative treatment to modulate anemia and the related symptoms of severe β-thalassemia and sickle cell disease (SCD). Hydroxyurea (HU) is the first US FDA-approved HbF inducer for treating SCD. However, approximately 25% of the patients with SCD do not respond to HU. A previous study identified TN1 (1) as a small-molecule HbF inducer. However, this study found that the poor potency and oral bioavailability of compound 1 limits the development of this inducer for clinical use. To develop drug-like compounds, further structure-activity relationship studies on the purine-based structure of 1 were conducted. Herein, we report our discovery of a more potent inducer, compound 13a, that can efficiently induce γ-globin gene expression at non-cytotoxic concentrations. The molecular mechanism of 13a, for the regulation HbF expression, was also investigated. In addition, we demonstrated that oral administration of 13a can ameliorate anemia and the related symptoms in SCD mice. The results of this study suggest that 13a can be further developed as a novel agent for treating hemoglobinopathies, such as β-thalassemia and SCD.
原文英語
文章編號112938
期刊European Journal of Medicinal Chemistry
209
DOIs
出版狀態已發佈 - 1月 2021

ASJC Scopus subject areas

  • 藥理
  • 藥物發現
  • 有機化學

指紋

深入研究「Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease」主題。共同形成了獨特的指紋。

引用此